company background image
VRDN

Viridian Therapeutics NasdaqCM:VRDN Stock Report

Last Price

US$35.80

Market Cap

US$1.4b

7D

-2.0%

1Y

79.1%

Updated

07 Feb, 2023

Data

Company Financials +

Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Mkt Cap: US$1.4b

VRDN Stock Overview

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.

VRDN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Viridian Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Viridian Therapeutics
Historical stock prices
Current Share PriceUS$35.80
52 Week HighUS$39.00
52 Week LowUS$9.47
Beta1.01
1 Month Change30.37%
3 Month Change88.62%
1 Year Change79.09%
3 Year Change186.00%
5 Year Change-56.61%
Change since IPO-80.28%

Recent News & Updates

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Recent updates

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08
Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22
An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Viridian Therapeutics Q2 2022 Earnings Preview

Aug 12

Viridian Therapeutics gets a new COO

Jun 23

Viridian Therapeutics (VRDN) Investor Presentation - Slideshow

Jun 08

Viridian Therapeutics reports Q1 results

May 06

Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity

Dec 08

Shareholder Returns

VRDNUS BiotechsUS Market
7D-2.0%-0.8%0.9%
1Y79.1%3.9%-10.9%

Return vs Industry: VRDN exceeded the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: VRDN exceeded the US Market which returned -9.6% over the past year.

Price Volatility

Is VRDN's price volatile compared to industry and market?
VRDN volatility
VRDN Average Weekly Movement9.0%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: VRDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VRDN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200650Jonathan Violinhttps://www.viridiantherapeutics.com

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.

Viridian Therapeutics, Inc. Fundamentals Summary

How do Viridian Therapeutics's earnings and revenue compare to its market cap?
VRDN fundamental statistics
Market CapUS$1.44b
Earnings (TTM)-US$113.03m
Revenue (TTM)US$1.88m

766.0x

P/S Ratio

-12.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VRDN income statement (TTM)
RevenueUS$1.88m
Cost of RevenueUS$83.97m
Gross Profit-US$82.09m
Other ExpensesUS$30.95m
Earnings-US$113.03m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.81
Gross Margin-4,364.17%
Net Profit Margin-6,009.30%
Debt/Equity Ratio1.1%

How did VRDN perform over the long term?

See historical performance and comparison